Weâre all rooting for you ð November 14, 2023 | [Read Online]( [Follow Me on X]((new)! *Sponsored by Psycheceutical Bioscience Hey Boardroom, how you doing? In honor of Veteranâs Day this past weekend, my wife and I watched one of our favorite movies based on a true story â Hacksaw Ridge. My wife doesn't usually like war movies, but she loves this one, especially the part, âHelp me get one more, Lord.â What a true hero and a humble man. But it had me thinking about the soldiers that survived, including Desmond, and the trauma they must have to deal with all their lives. So it was interesting when my newest partner in the Boardroom, [Psycheceutical Bioscience](, contacted me about potentially life-changing research the company is doing to help people suffering from PTSD and other mental disorders (a market of 300 million plus people). The company recently released [THIS ARTICLE]( about its NeuroDirect⢠topical ketamine formula for the treatment of PTSD that targets NMDA receptors â without entering the bloodstream. According to NeuroDirectâs developing physician, Dr. Aung-Din, âThe theory is that this precise, nonsystemic action allows ketamine to speak directly to brain regions involved with PTSD symptoms.â If all aligns, NeuroDirect creams could rein over pills and injections as one of the most prescribed technologies for targeted healing. Initial research is ongoing, but early observational data has been positive. For example, one patient diagnosed with PTSD, heavy metal poisoning, anxiety disorder, and fibromyalgia felt âchiâ and âat peace,â as well as a drastic mood improvement after using the cream. You can read about all their studies and initial findings [HERE](.  It has everybody extremely excited⦠Another person extremely excited about Psycheceuticalâs potential is one of the original âSharksâ from Shark Tank , Kevin Harrington. A recent [Benzinga Article]( reinforces the proposition that psychedelics will be the future of mental health care: Kevin Harrington thinks safe psychedelic medicines without the âtripâ are the future of mental health care, and has put his support behind Psycheceutical. So how can people like you or me play a part in helping move this ball forward? By doing a deep dive into the company and seeing if it is worth an investment.  Psycheceutical (trading on the OTC as BWVI) is conducting a [Reg CF campaign through Wefunder]( to further its research and development, including trials of its ketamine topical for the treatment of PTSD. You might be asking, âWhy is the company raising funds via a CF if itâs already public?â CEO Chad Harman explains in our recent [Boardroom interview]( that theyâre doing this to give a wider base of investors the opportunity to invest, as increasing the number of investors will allow the company to uplist to a bigger exchange. In a nutshell, by investing through Wefunder, new investors gain more favorable terms and a better entry price than simply going directly to the exchange. Please take some time to dig into the details as these types of partnerships could have far-reaching implications. Two good places to review are the companyâs [fundraising page]( and their [investor presentation](.   Thatâs it for now, thanks for reading! *Sponsored content. Like all investments, this investment involves substantial risk. Please see full disclosures below. Questions or concerns about our products? Email [Support@boardroominvesting.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand RagingBull.com, LLCâs issuer-paid advertisement disclaimer and disclosure policy located at [(. ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (âRaging Bullâ) seventy five hundred dollars in total to run advertisements enhancing public awareness of the company. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Raging Bull strongly recommends you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. RagingBull.com, LLC shall be entitled to recover attorneysâ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneysâ fees, costs and disbursements in addition to any other relief to which it may be entitled. Update your email preferences or unsubscribe [here]( © 2023 Boardroom 62 Calef Hwy. #233
Lee, NH 03861, United States of America